Mirae Asset Global Investments Co. Ltd. Sells 49,894 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Mirae Asset Global Investments Co. Ltd. trimmed its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 14.7% during the fourth quarter, HoldingsChannel.com reports. The fund owned 289,838 shares of the company’s stock after selling 49,894 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Hims & Hers Health were worth $2,580,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Osaic Holdings Inc. boosted its stake in Hims & Hers Health by 29.1% in the second quarter. Osaic Holdings Inc. now owns 6,213 shares of the company’s stock worth $58,000 after purchasing an additional 1,400 shares in the last quarter. Virtu Financial LLC boosted its stake in Hims & Hers Health by 8.4% in the fourth quarter. Virtu Financial LLC now owns 18,441 shares of the company’s stock worth $118,000 after purchasing an additional 1,430 shares in the last quarter. ProShare Advisors LLC boosted its stake in Hims & Hers Health by 11.3% in the second quarter. ProShare Advisors LLC now owns 15,899 shares of the company’s stock worth $149,000 after purchasing an additional 1,614 shares in the last quarter. Pathstone Family Office LLC boosted its stake in Hims & Hers Health by 2.8% in the third quarter. Pathstone Family Office LLC now owns 65,876 shares of the company’s stock worth $414,000 after purchasing an additional 1,824 shares in the last quarter. Finally, Credit Suisse AG boosted its stake in Hims & Hers Health by 2.2% in the first quarter. Credit Suisse AG now owns 103,690 shares of the company’s stock worth $1,029,000 after purchasing an additional 2,281 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Jefferies Financial Group reissued a “hold” rating and issued a $15.00 price objective (down previously from $17.00) on shares of Hims & Hers Health in a research note on Tuesday. Citigroup upped their price target on Hims & Hers Health from $12.00 to $16.00 and gave the company a “buy” rating in a research note on Tuesday, February 27th. Leerink Partnrs reiterated a “market perform” rating on shares of Hims & Hers Health in a report on Monday, February 26th. SVB Leerink assumed coverage on Hims & Hers Health in a report on Monday, February 26th. They issued a “market perform” rating and a $10.00 price target on the stock. Finally, Canaccord Genuity Group assumed coverage on Hims & Hers Health in a report on Wednesday, April 10th. They issued a “buy” rating and a $20.00 price target on the stock. Five investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $14.85.

Hims & Hers Health Trading Down 0.6 %

Shares of HIMS opened at $12.34 on Friday. Hims & Hers Health, Inc. has a 1 year low of $5.65 and a 1 year high of $17.16. The stock has a market cap of $2.64 billion, a P/E ratio of -112.18 and a beta of 0.91. The stock’s 50-day moving average price is $13.47 and its two-hundred day moving average price is $9.80.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, February 26th. The company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.03. Hims & Hers Health had a negative return on equity of 7.21% and a negative net margin of 2.70%. The firm had revenue of $246.60 million for the quarter, compared to analysts’ expectations of $245.84 million. During the same quarter last year, the business earned ($0.05) earnings per share. The company’s revenue was up 47.4% compared to the same quarter last year. As a group, equities analysts forecast that Hims & Hers Health, Inc. will post 0.1 EPS for the current year.

Insiders Place Their Bets

In other Hims & Hers Health news, CEO Andrew Dudum sold 15,100 shares of the firm’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $9.01, for a total transaction of $136,051.00. Following the transaction, the chief executive officer now owns 51,653 shares in the company, valued at $465,393.53. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, insider Soleil Boughton sold 2,503 shares of the firm’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $13.95, for a total transaction of $34,916.85. Following the sale, the insider now owns 164,363 shares of the company’s stock, valued at $2,292,863.85. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Andrew Dudum sold 15,100 shares of the firm’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $9.01, for a total value of $136,051.00. Following the sale, the chief executive officer now directly owns 51,653 shares in the company, valued at approximately $465,393.53. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 675,838 shares of company stock worth $8,487,125. Insiders own 31.63% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.